PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.07%
Revenue growth at 50-75% of META's 16.06%. Martin Whitman would worry about competitiveness or product relevance.
7.31%
Gross profit growth at 75-90% of META's 8.32%. Bill Ackman would demand operational improvements to match competitor gains.
5.98%
EBIT growth below 50% of META's 94.39%. Michael Burry would suspect deeper competitive or cost structure issues.
5.98%
Operating income growth under 50% of META's 94.39%. Michael Burry would be concerned about deeper cost or sales issues.
-2.06%
Negative net income growth while META stands at 5.87%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-0.93%
Negative EPS growth while META is at 7.32%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-0.94%
Negative diluted EPS growth while META is at 7.32%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.79%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-1.15%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
1.12%
OCF growth under 50% of META's 49.74%. Michael Burry might suspect questionable revenue recognition or rising costs.
-0.36%
Negative FCF growth while META is at 1630.38%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
487.85%
10Y revenue/share CAGR under 50% of META's 1946.82%. Michael Burry would suspect a lasting competitive disadvantage.
153.30%
5Y revenue/share CAGR at 75-90% of META's 177.59%. Bill Ackman would encourage strategies to match competitor’s pace.
76.30%
3Y revenue/share CAGR 1.25-1.5x META's 65.65%. Bruce Berkowitz might see better product or regional expansions than the competitor.
416.64%
10Y OCF/share CAGR under 50% of META's 2049.19%. Michael Burry would worry about a persistent underperformance in cash creation.
147.60%
5Y OCF/share CAGR 1.25-1.5x META's 111.80%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
74.84%
3Y OCF/share CAGR similar to META's 73.46%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
382.23%
Below 50% of META's 10814.15%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
585.69%
5Y net income/share CAGR above 1.5x META's 22.05%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
36.38%
Positive short-term CAGR while META is negative. John Neff would see a clear advantage in near-term profit trajectory.
264.85%
Below 50% of META's 978.66%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
80.83%
5Y equity/share CAGR is in line with META's 89.30%. Walter Schloss would see parallel mid-term profitability and retention policies.
35.82%
3Y equity/share CAGR similar to META's 35.07%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 5Y dividend/share CAGR while META stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
No Data
No Data available this quarter, please select a different quarter.
11.28%
AR growth well above META's 19.94%. Michael Burry fears inflated revenue or higher default risk in the near future.
-15.40%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
1.96%
Asset growth at 50-75% of META's 3.82%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
1.80%
50-75% of META's 2.99%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
2.62%
Debt growth far above META's 2.67%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-0.06%
Our R&D shrinks while META invests at 6.55%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
16.65%
SG&A growth well above META's 6.91%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.